<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">683</article-id><article-id pub-id-type="doi">10.25692/ACEN.2020.3.6</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">LYVE-1 expression in the endothelium of newly formed vessels of carotid atherosclerotic plaque</article-title><trans-title-group xml:lang="ru"><trans-title>Экспрессия LYVE-1 в эндотелии вновь образованных сосудов атеросклеротической бляшки каротидного синуса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Evdokimenko</surname><given-names>Anna N.</given-names></name><name xml:lang="ru"><surname>Евдокименко</surname><given-names>Анна Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>evdokimenko@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kulichenkova</surname><given-names>Ksenia N.</given-names></name><name xml:lang="ru"><surname>Куличенкова</surname><given-names>Ксения Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>evdokimenko@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gulevskaya</surname><given-names>Tatiana S.</given-names></name><name xml:lang="ru"><surname>Гулевская</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>evdokimenko@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Center of Neurology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научный центр неврологии»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-09-14" publication-format="electronic"><day>14</day><month>09</month><year>2020</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>43</fpage><lpage>52</lpage><history><date date-type="received" iso-8601-date="2020-09-14"><day>14</day><month>09</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Evdokimenko A.N., Kulichenkova K.N., Gulevskaya T.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Evdokimenko A.N., Kulichenkova K.N., Gulevskaya T.S.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Evdokimenko A.N., Kulichenkova K.N., Gulevskaya T.S.</copyright-holder><copyright-holder xml:lang="ru">Evdokimenko A.N., Kulichenkova K.N., Gulevskaya T.S.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/683">https://annaly-nevrologii.com/pathID/article/view/683</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>The discovery of specific markers of lymphatic endothelium, including LYVE-1, has led to a much better understanding of the structure and function of the lymphatic system. It has been shown that lymphatic system regulates immune responses, reverse cholesterol transport, and inflammation in atherosclerosis. LYVE-1 plays an important role in activating the function of the lymphatic system and is also one of the first markers of lymphangiogenesis. There are few morphological studies of lymphatic vessels in atherosclerotic plaques, and the obtained data are contradictory.</p> <p>The <bold>aim</bold> of the study was to characterize the LYVE-1 receptor expression in the endothelium of newly formed vessels in carotid atherosclerotic plaques and to evaluate its relationship with the plaque structure. </p> <p><bold>Materials and methods</bold>. 34 carotid atherosclerotic plaques obtained during carotid endarterectomies were investigated using histological and immunohistochemical techniques. The density of LYVE-1+ vessels per 1 cm2 of plaque, combined expression of LYVE-1 and CD34, proportion of atheromatosis and calcifications, as well as severity of dust-like calcification, haemorrhage, overall macrophage response (CD68+), and plaque infiltration by M2 macrophage (CD206+) were evaluated. </p> <p><bold>Results.</bold> LYVE-1+ vessels were detected in 32 carotid atherosclerotic plaques, with a range of 5.7–1698 per 1 cm2 of the plaque (37.4 [15.3; 76]). Marker expression was heterogeneous: it was observed in all or only some endothelial cells of the newly formed vessel, and the expression intensity varied from weak to strong. Both CD34+LYVE-1+ and CD34+LYVE-1– vessel phenotypes were identified. A relationship between endothelial LYVE-1 expression and the structure or type of plaque was not established, except for the macrophage response. The density of LYVE-1+ vessels in atherosclerotic plaques correlated weakly with the overall macrophage response (r = 0.37; p = 0.03), more significantly with the number of anti-inflammatory M2 macrophages (r = 0.47; p = 0.005), especially for vessels with moderate and strong marker expression (r = 0.56; p = 0.0006). </p> <p><bold>Conclusion.</bold> The combined expression of LYVE-1 and CD34 in the endothelium of plaque neovessels was demonstrated for the first time, and a possible association between endothelial LYVE-1 expression in newly formed vessels and the reparative processes in atherosclerotic plaques was shown.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> С открытием специфических маркеров лимфатического эндотелия, одним из которых является LYVE-1, значительно улучшилось представление о структуре и функции лимфатической системы. Установлено, что при атеросклерозе она регулирует иммунные ответы, обратный транспорт холестерина и воспаление. LYVE-1 играет немаловажную роль в реализации функции лимфатической системы, а также является одним из первых маркеров начала лимфангиогенеза. Морфологические исследования лимфатических сосудов в атеросклеротических бляшках (АСБ) человека немногочисленны, а полученные данные противоречивы.</p> <p><bold>Цель </bold>— охарактеризовать экспрессию рецептора LYVE-1 в эндотелии вновь образованных сосудов АСБ каротидного синуса (КС) и оценить ее взаимосвязь со структурой бляшки.</p> <p><bold>Материалы и методы. </bold>Проведено гистологическое и иммуногистохимическое исследование 34 АСБ КС, полученных при каротидной эндартерэктомии. Оценивали плотность расположения LYVE-1+-сосудов в 1 см2 АСБ, сочетанную экспрессию LYVE-1 и CD34, объемную долю ате- роматоза и кальцификатов, а также степень выраженности пылевидного обызвествления, кровоизлияний, общей макрофагальной реакции (CD68+) и инфильтрации АСБ М2-фракцией макрофагов (CD206+).</p> <p><bold>Результаты. </bold>LYVE-1+-сосуды выявлены в 32 АСБ КС, их количество составило 5,7–1698 (37,4 [15,3; 76]) в 1 см2 бляшки. Экспрессия маркера была неоднородна: наблюдалась во всех или только в отдельных эндотелиоцитах вновь образованного сосуда, интенсивность экспрессии варьировала от слабой до выраженной. Отмечены сосуды фенотипа как CD34+LYVE-1+, так и CD34+LYVE-1–. Взаимосвязи экспрессии LYVE-1 в эндотелии со структурой или типом бляшки не выявлено, за исключением макрофагальной реакции. Плотность расположения LYVE-1+- сосудов в АСБ коррелировала слабо с общей макрофагальной реакцией (r = 0,37; р = 0,03), более значимо — с количеством противовоспалительных М2-макрофагов (r = 0,47; р = 0,005), в особенности это касалось сосудов с умеренной и выраженной интенсивностью экспрессии маркера (r = 0,56; р = 0,0006).</p> <p><bold>Заключение.</bold> Впервые продемонстрирована сочетанная экспрессия LYVE-1 и CD34 в эндотелии сосудов АСБ, а также показана возможная связь экспрессии LYVE-1 в эндотелии вновь образованных сосудов с репаративными процессами в АСБ.</p></trans-abstract><kwd-group xml:lang="en"><kwd>carotid atherosclerotic plaque</kwd><kwd>lymphangiogenesis</kwd><kwd>neovascularization</kwd><kwd>M2 macrophages</kwd><kwd>LYVE-1</kwd><kwd>CD206</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>атеросклеротическая бляшка каротидного синуса</kwd><kwd>лимфангиогенез</kwd><kwd>неоваскуляризация</kwd><kwd>М2-макрофаги</kwd><kwd>LYVE-1</kwd><kwd>CD206</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Lemole G.M.Sr. The role of lymphstasis in atherogenesis revisited. Ann Thorac Surg 2016; 101: 2029. DOI: 10.1016/j.athoracsur.2015.09.093. PMID: 27106458.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zheng Z., Ren K., Peng X. et al. Lymphatic vessels: a potential approach to the treatment of atherosclerosis? Lymphat Res Biol 2018; 16: 498–506. DOI: 10.1089/lrb.2018.0015. PMID: 30272526.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kutkut I., Meens M.J., Mckee T.A. et al. Lymphatic vessels: an emerging actor in atherosclerotic plaque development. Eur J Clin Invest 2015; 45: 100–108. DOI: 10.1111/eci.12372. PMID: 25388153.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Csányi G., Singla B. Arterial lymphatics in atherosclerosis: old questions, new insights, and remaining challenges. J Clin Med 2019; 8: 495. DOI: 10.3390/ jcm8040495. PMID: 30979062.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Drozdz K., Janczak D., Dziegiel P. et al. Adventitial lymphatics of internal carotid artery in healthy and atherosclerotic vessels. Folia Histochem Cytobiol 2008; 46: 433–436. DOI: 10.2478/v10042-008-0083-7. PMID:19141394.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Drozdz K., Janczak D., Dziegiel P. et al. Adventitial lymphatics and atherosclerosis. Lymphology 2012; 45: 26–33. PMID: 22768470.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kholová I., Dragneva G., Čermáková P. et al. Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 2011; 41: 487–497. DOI: 10.1111/j.1365-2362.2010.02431.x. PMID: 21128936.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Eliska O., Eliskova M., Miller A.J. The absence of lymphatics in normal and atherosclerotic coronary arteries in man: a morphologic study. Lymphology 2006; 39: 76–83. PMID: 16910098.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Banerji S., Ni J., Wang S.X. et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789–801. DOI: 10.1083/jcb.144.4.789. PMID: 10037799.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Jackson D.G. Hyaluronan in the lymphatics: the key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biol 2019; 78–79: 219–235. DOI: 10.1016/j.matbio.2018.02.001. PMID: 29425695.</mixed-citation></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Wróbel T., Dziegiel P., Mazur G. et al. LYVE-1 expression on high endothelial venules (HEVs) of lymph nodes. Lymphology 2005; 38: 107–110. PMID: 16353487.</mixed-citation><mixed-citation xml:lang="ru">Wróbel T., Dziegiel P., Mazur G. et al. LYVE-1 expression on high endo- thelial venules (HEVs) of lymph nodes. Lymphology 2005; 38: 107–110. PMID: 16353487.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Schledzewski K., Falkowski M., Moldenhauer G. et al. Lympathic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macropahages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: Implications for the assessment of lymphangiogen. J Pathol 2006; 209: 67–77. DOI: 10.1002/path.1942. PMID: 16482496.</mixed-citation><mixed-citation xml:lang="ru">Schledzewski K., Falkowski M., Moldenhauer G. et al. Lympathic en- dothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macropahages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: Implications for the assessment of lymphangiogen. J Pathol 2006; 209: 67–77. DOI: 10.1002/path.1942. PMID: 16482496.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><mixed-citation>Krolikoski M., Monslow J., Puré E. The CD44-HA axis and inflammation in atherosclerosis: a temporal perspective. Matrix Biol 2019; 78–79: 201–218. DOI: 10.1016/j.matbio.2018.05.007. PMID: 29792915.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Escobedo N., Oliver G. Lymphangiogenesis: origin, specification, and cell fate determination. Annu Rev Cell Dev Biol 2016; 32: 677–691. DOI: 10.1146/ annurev-cellbio-111315-124944. PMID: 27298093.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Stary H.C. Natural history and histological classification of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1177–1178. DOI: 10.1161/01. ATV.20.5.1177. PMID: 10807728.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Baumhueter S., Dybdal N., Kyle C., Lasky L.A. Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood 1994;</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Shi Q., VandeBerg J.L. Experimental approaches to derive CD34+ progenitors from human and nonhuman primate embryonic stem cells. Am J Stem Cells 2015; 4: 32–37. PMID: 25973329.</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Sidney L.E., Branch M.J., Dunphy S.E. et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 2014; 32: 1380–1389. DOI: 10.1002/stem.1661. PMID: 24497003.</mixed-citation><mixed-citation xml:lang="ru">Sidney L.E., Branch M.J., Dunphy S.E. et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells 2014; 32: 1380– 1389. DOI: 10.1002/stem.1661. PMID: 24497003.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><mixed-citation>Fiedler U., Christian S., Koidl S. et al. The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol 2006; 168: 1045–1053. DOI: 10.2353/ajpath.2006.050554. PMID: 16507917.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Hong Y.-K., Harvey N., Noh Y.-H. et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 2002; 225: 351–357. DOI: 10.1002/dvdy.10163. PMID: 12412020.</mixed-citation></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Sauter B., Foedinger D., Sterniczky B. et al. Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. J Histochem Cytochem 1998; 46: 165–176. DOI: 10.1177/002215549804600205. PMID: 9446823.</mixed-citation><mixed-citation xml:lang="ru">Sauter B., Foedinger D., Sterniczky B. et al. Immunoelectron microsco- pic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymph- angioma, and hemangioma in situ. J Histochem Cytochem 1998; 46: 165–176. DOI: 10.1177/002215549804600205. PMID: 9446823.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><mixed-citation>Meng F.-W., Liu F.-S., Liu W.-H. et al. Formation of new lymphatic vessels in glioma: an immunohistochemical analysis. Neuropathology 2020; 40: 215–223. DOI: 10.1111/neup.12625. PMID: 31960509.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zhang H.-F., Wang Y.-L., Tan Y.-Z. et al. Enhancement of cardiac lymph- angiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C. Basic Res Cardiol 2019; 114: 43. DOI: 10.1007/s00395-019-0752-z. PMID: 31587086.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Meng F.-W., Gao Z.-L., Li L. et al. Reconstruction of lymphatic vessels in the mouse tail after cupping therapy. Folia Morphol (Warsz) 2020; 79: 98–104. DOI: 10.5603/FM.a2019.0044. PMID: 30993665.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Salven P., Mustjoki S., Alitalo R. et al. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101: 168–172. DOI: 10.1182/blood-2002-03-0755. PMID: 12393704.</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Schmeisser A., Garlichs C.D., Zhang H. et al. Monocytes coexpress endo- thelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001; 49: 671–680. DOI: 10.1016/S0008-6363(00)00270-4. PMID: 11166280.</mixed-citation><mixed-citation xml:lang="ru">Schmeisser A., Garlichs C.D., Zhang H. et al. Monocytes coexpress endothelial and macrophagocytic lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 2001; 49: 671–680. DOI: 10.1016/S0008-6363(00)00270-4. PMID: 11166280.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Cursiefen C., Chen L., Borges L.P. et al. VEGF-A stimulates lymphangio- genesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040–1050. DOI: 10.1172/JCI20465. PMID: 15057311.</mixed-citation><mixed-citation xml:lang="ru">Cursiefen C., Chen L., Borges L.P. et al. VEGF-A stimulates lymphangio- genesis and hemangiogenesis in inflammatory neovascularization via macro- phage recruitment. J Clin Invest 2004; 113: 1040–1050. DOI: 10.1172/JCI20465. PMID: 15057311.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Attout T., Hoerauf A., Dénécé G. et al. Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human Onchocerca nodule. PLoS One 2009; 4: e8234. DOI: 10.1371/journal.pone.0008234. PMID: 20011036.</mixed-citation><mixed-citation xml:lang="ru">Attout T., Hoerauf A., Dénécé G. et al. Lymphatic vascularisation and in- volvement of Lyve-1+ macrophages in the human Onchocerca nodule. PLoS One 2009; 4: e8234. DOI: 10.1371/journal.pone.0008234. PMID: 20011036.</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><mixed-citation>Dunmore B.J., McCarthy M.J., Naylor A.R., Brindle N.P.J. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg 2007; 45: 155–159. DOI: 10.1016/j.jvs.2006.08.072. PMID: 17210401.</mixed-citation></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Sluimer J.C., Kolodgie F.D., Bijnens A.P.J.J. et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions. Relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 2009; 53: 1517–1527. DOI: 10.1016/j. jacc.2008.12.056. PMID: 19389562.</mixed-citation><mixed-citation xml:lang="ru">Sluimer J.C., Kolodgie F.D., Bijnens A.P.J.J. et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions. Relevance of compromised structural integrity for intraplaque mi- crovascular leakage. J Am Coll Cardiol 2009; 53: 1517–1527. DOI: 10.1016/j. jacc.2008.12.056. PMID: 19389562.</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Torzicky M., Viznerova P., Richter S. et al. Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells. J Invest Dermatol 2012; 132: 1149–1157. DOI: 10.1038/jid.2011.420. PMID: 22189791.</mixed-citation><mixed-citation xml:lang="ru">Torzicky M., Viznerova P., Richter S. et al. Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic trans- migration of human dendritic cells. J Invest Dermatol 2012; 132: 1149–1157. DOI: 10.1038/jid.2011.420. PMID: 22189791.</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><mixed-citation>Kiesewetter A., Cursiefen C., Eming S.A., Hos D. Phase-specific functions of macrophages determine injury-mediated corneal hem- and lymphangiogenesis. Sci Rep 2019; 9: 308. DOI: 10.1038/s41598-018-36526-6. PMID: 30670724.</mixed-citation></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Sarbaeva N.N., Ponomareva Yu.V., Milyakova M.N. [Macrophages: diversity of phenotypes and functions, interaction with foreign materials]. Geny i kletki 2016; 11(1): 9–17. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Сарбаева Н.Н., Пономарева Ю.В., Милякова М.Н. Макрофаги: разнообразие фенотипов и функций, взаимодействие с чужеродными материалами. Гены и клетки 2016; 11(1): 9–17.</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">de Gaetano M., Crean D., Barry M., Belton O. M1- and M2-Type macro- phage responses are predictive of adverse outcomes in human atherosclerosis. Front Immunol 2016; 7: 275. DOI: 10.3389/fimmu.2016.00275. PMID: 27486460.</mixed-citation><mixed-citation xml:lang="ru">de Gaetano M., Crean D., Barry M., Belton O. M1- and M2-Type macrophage responses are predictive of adverse outcomes in human atherosclerosis. Front Immunol 2016; 7: 275. DOI: 10.3389/fimmu.2016.00275. PMID: 27486460.</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><mixed-citation>Bieniasz-Krzywiec P., Martín-Pérez R., Ehling M. et al. Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer. Cell Metab 2019; 30: 917–936.e10. DOI: 10.1016/j.cmet.2019.07.015. PMID: 31447322.</mixed-citation></ref></ref-list></back></article>
